Search Results - "Moor, Catharina C."

Patient-centered care in pulmonary fibrosis: access, anticipate, and act by Hofman, Delian E, Magrì, Tonia, Moor, Catharina C, Richeldi, Luca, Wijsenbeek, Marlies S, Waseda, Yuko

“…Abstract Comprehensive care integrates individual patient needs and is highly valued for patients with pulmonary fibrosis (PF). The importance of a…”
Get full text

A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease by Maher, Toby M, Schiffman, Courtney, Kreuter, Michael, Moor, Catharina C, Nathan, Steven D, Axmann, Judit, Belloni, Paula, Bengus, Monica, Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Wijsenbeek, Marlies S

“…Abstract Background Patients with interstitial lung disease (ILD) require regular physician visits and referral to specialist ILD clinics. Difficulties or…”
Get full text

Educational aspects of rare and orphan lung diseases by Alfaro, Tiago M, Wijsenbeek, Marlies S, Powell, Pippa, Stolz, Daiana, Hurst, John R, Kreuter, Michael, Moor, Catharina C

“…People with rare lung diseases often suffer the burden of delayed diagnosis, limited treatment options, and difficulties in finding expert physicians. One of…”
Get full text

Differentiating interstitial lung diseases from other respiratory diseases using electronic nose technology by van der Sar, Iris G, Wijsenbeek, Marlies S, Braunstahl, Gert-Jan, Loekabino, Jason O, Dingemans, Anne-Marie C, In 't Veen, Johannes C. C. M, Moor, Catharina C

“…Abstract Introduction Interstitial lung disease (ILD) may be difficult to distinguish from other respiratory diseases due to overlapping clinical presentation…”
Get full text

Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study by Miedema, Jelle R, Moor, Catharina C, Veltkamp, Marcel, Baart, Sara, Lie, Natascha S L, Grutters, Jan C, Wijsenbeek, Marlies S, Mostard, Rémy L M

“…Pirfenidone slows down disease progression in idiopathic pulmonary fibrosis (IPF). Recent studies suggest a treatment effect in progressive pulmonary fibrosis…”
Get full text

Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population by Kahlmann, Vivienne, Moor, Catharina C, Veltkamp, Marcel, Wijsenbeek, Marlies S

“…Currently prednisone is the first-line pharmacological treatment option for pulmonary sarcoidosis. Methotrexate is used as second-line therapy and seems to…”
Get full text

Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE by Nakshbandi, Gizal, Moor, Catharina C, Antoniou, Katerina, Cottin, Vincent, Hoffmann-Vold, Anna-Maria, Koemans, Edwin A, Kreuter, Michael, Molyneaux, Philip L, Wuyts, Wim A, Wijsenbeek, Marlies S

“…Pulmonary fibrosis (PF) is caused by a heterogeneous group of diseases, with a high inter-individual variability in disease trajectory. Identifying disease…”
Get full text

Desquamative interstitial pneumonia: a systematic review of its features and outcomes by Hellemons, Merel E, Moor, Catharina C, von der Thüsen, Jan, Rossius, Mariska, Odink, Arlette, Thorgersen, Laila Haugen, Verschakelen, Johny, Wuyts, Wim, Wijsenbeek, Marlies S, Bendstrup, Elisabeth

“…Desquamative Interstitial Pneumonia (DIP) is a rare form of idiopathic interstitial pneumonia (IIP). Data on clinical features, aetiology, prognosis and effect…”
Get full text

Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study by Kahlmann, Vivienne, Janssen Bonás, Montse, Moor, Catharina C, van Moorsel, Coline H. M, Kool, Mirjam, Kraaijvanger, Raisa, Grutters, Jan C, Overgaauw, Mayka, Veltkamp, Marcel, Wijsenbeek, Marlies S, Koopman, B, Geelhoed, J. J. M, Janssen, R, Jonkers, R.E, Kramer, H, Moonen, L, Mostard, R. L. M, Nossent, E. J, Overbeek, M. J, van Rijswijk, R.H. N. A. J, Wagenaar, M, Walen, S, Wielders, P. L. M. L, Loth, D. W, Bogaarts, B. A. H. A, van der Maten, J

“…Abstract Background Treatment of pulmonary sarcoidosis is recommended in case of significant symptoms, impaired or deteriorating lung function. Evidence-based…”
Get full text

Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era by Nakshbandi, Gizal, Moor, Catharina C., Johannson, Kerri A., Maher, Toby M., Kreuter, Michael, Wijsenbeek, Marlies S.

“…Interstitial lung diseases (ILD) comprise a group of pulmonary diseases characterised by diffuse parenchymal abnormalities, which can lead to irreversible…”
Get full text

Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis by Moor, Catharina C, Heukels, Peter, Kool, Mirjam, Wijsenbeek, Marlies S

“…Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease which has a major impact on patients' quality of life (QOL). Except for lung…”
Get full text

Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey by Moor, Catharina C, Wijsenbeek, Marlies S, Balestro, Elisabetta, Biondini, Davide, Bondue, Benjamin, Cottin, Vincent, Flewett, Ron, Galvin, Liam, Jones, Steve, Molina-Molina, Maria, Planas-Cerezales, Lurdes, Prasse, Antje, Prosch, Helmut, Russell, Anne-Marie, Viegas, Michel, Wanke, Guenther, Wuyts, Wim, Kreuter, Michael, Bonella, Francesco

“…Pulmonary fibrosis (PF) and its most common form, idiopathic pulmonary fibrosis (IPF), are chronic, progressive diseases resulting in increasing loss of lung…”
Get full text

ERS International Congress 2022: highlights from the Interstitial Lung Diseases Assembly by Karampitsakos, Theodoros, Diep, Phuong Phuong, Loth, Daan W, Nadeem, Iftikhar, Khurtsidze, Elene, Wijsenbeek, Marlies S, Wuyts, Wim A, Bargagli, Elena, Froidure, Antoine, Spagnolo, Paolo, Veltkamp, Marcel, Molina-Molina, Maria, McCarthy, Cormac, Antoniou, Katerina M, Kreuter, Michael, Moor, Catharina C

“…This article contains a selection of scientific highlights in the field of interstitial lung diseases (ILDs) presented at the hybrid European Respiratory…”
Get full text

Home monitoring for cystic fibrosis: The future is now by Moor, Catharina C.

Get full text

Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World by Polke, Markus, Kondoh, Yasuhiro, Wijsenbeek, Marlies, Cottin, Vincent, Walsh, Simon L. F., Collard, Harold R., Chaudhuri, Nazia, Avdeev, Sergey, Behr, Jürgen, Calligaro, Gregory, Corte, Tamera J., Flaherty, Kevin, Funke-Chambour, Manuela, Kolb, Martin, Krisam, Johannes, Maher, Toby M., Molina Molina, Maria, Morais, Antonio, Moor, Catharina C., Morisset, Julie, Pereira, Carlos, Quadrelli, Silvia, Selman, Moises, Tzouvelekis, Argyrios, Valenzuela, Claudia, Vancheri, Carlo, Vicens-Zygmunt, Vanesa, Wälscher, Julia, Wuyts, Wim, Bendstrup, Elisabeth, Kreuter, Michael

“…Background: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a severe complication associated with a high mortality. However, evidence and…”
Get full text

ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly by Guler, Sabina A, Cuevas-Ocaña, Sara, Nasser, Mouhamad, Wuyts, Wim A, Wijsenbeek, Marlies S, Froidure, Antoine, Bargagli, Elena, Renzoni, Elisabetta A, Veltkamp, Marcel, Spagnolo, Paolo, Nunes, Hilario, McCarthy, Cormac, Molina-Molina, Maria, Bonella, Francesco, Poletti, Venerino, Kreuter, Michael, Antoniou, Katerina M, Moor, Catharina C

“…This article provides an overview of scientific highlights in the field of interstitial lung disease (ILD), presented at the virtual European Respiratory…”
Get full text

Managing Fatigue in Patients With Interstitial Lung Disease by Kahlmann, Vivienne, Moor, Catharina C., Wijsenbeek, Marlies S.

“…Fatigue is one of the most burdensome symptoms in interstitial lung disease (ILD) and can have a major impact on quality of life, social interactions, and work…”
Get full text

Highlights of the ERS Lung Science Conference and Sleep and Breathing Conference 2021 and the new ECMC members by Goodwin, Amanda T, Karadoğan, Dilek, De Santis, Martina M, Alsafadi, Hani N, Hawthorne, Ian, Bradicich, Matteo, Siciliano, Matteo, Şahin Duyar, Sezgi, Targa, Adriano, Meszaros, Martina, Fanaridis, Michail, Gille, Thomas, Keir, Holly R, Moor, Catharina C, Lichtblau, Mona, Ubags, Niki D, Cruz, Joana

“…https://bit.ly/2RSDP40…”
Get full text

Sexual Dysfunction in Patients With Sarcoidosis by Moor, Catharina C., Gur-Demirel, Yasmin, Koudstaal, Thomas, Miedema, Jelle R.

Get full text

Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial by Moor, Catharina C, Mostard, Rémy L M, Grutters, Jan C, Bresser, Paul, Aerts, Joachim G J V, Chavannes, Niels H, Wijsenbeek, Marlies S

“…Idiopathic pulmonary fibrosis (IPF) is a deadly disease with increasingly impaired health-related quality of life (HRQOL). EHealth technologies facilitate…”
Get full text